Drawing for WHY FUNGUS IS YOUR GUT'S BEST FRIEND

USPTO serial 87504901

WHY FUNGUS IS YOUR GUT'S BEST FRIEND

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
THOMAS, AMY E
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with WHY FUNGUS IS YOUR GUT'S BEST FRIEND?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

BRIAN E. TURUNG

BRIAN E. TURUNG FAY SHARPE LLP1228 EUCLID AVENUECLEVELAND, OH 44115UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Probiotic supplements; vitamin and mineral supplements; vitamin supplements; whey protein supplements; dietary supplement drink mixes; dietary supplement for eliminating toxins from the intestinal tract; enzyme food supplements; herbal supplements; mineral supplements; multi-vitamin preparations; natural herbal supplements; nutraceuticals for use as a dietary supplement; nutritional supplement for eliminating toxins from the intestinal tract; nutritional supplement shakes; nutritional supplements, namely, probiotic compositions; nutritional supplements, namely, carbohydrates in powdered form; powdered nutritional supplement concentrate; vitamin and mineral supplements in powder, tablet, liquid, capsule or spray form; mineral supplements in powder, tablet, liquid, capsule or spray form; dietary supplements in powder, tablet, liquid, capsule or spray form; food supplements providing a source of vitamins and/or minerals and/or essential fatty acids and/or probiotic cultures in powder, tablet, liquid, capsule or spray form; nutritional supplements for human consumption providing a source of vitamins and/or minerals and/or essential fatty acids and/or probiotic cultures in powder, tablet, liquid, capsule or spray form; herbal supplements for general health and well-being, namely, in powder, tablet, liquid, capsule or spray form; preparations in the nature of a vaginal probiotic for the treatment and/or prevention of bacterial or fungal vaginal infection; nutraceuticals for the treatment and/or prevention of bacterial vaginosis, vaginal discharge and odors, for preventing the growth of undesirable micro-organisms that can cause vaginal discharge and odor, killing bacteria that cause bacterial vaginosis, and for maintaining a desirable microflora in the vaginal cavity; micro-organisms culture for medical use, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's disease in which inflammation is present both in the small intestine and in the colon; pharmaceutical products containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and crohn's disease in which inflammation is present both in the small intestine and in the colon; pharmaceutical products, namely, probiotic lactic acid bacteria, probiotic bifidobacteria which are able to ferment and use the fibres in the human organism for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and crohn's disease in which inflammation is present both in the small intestine and in the colon, and dietary and nutritional supplements containing microorganisms and cultures of microorganisms, namely, probiotic lactic acid bacteria, probiotic bifidobacteria which are able to ferment and use the fibres in the human organism; pharmaceutical products for oral consumption, namely, capsules, tablets, solutions, suspensions, granules, and pellets in dried form, containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, including, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and crohn's disease in which inflammation is present both in the small intestine and in the colon, and dietary and nutritional supplements for oral consumption, namely, capsules, tablets, solutions, suspensions, granules, and pellets in dried form, containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans; microbial and biological preparations for improving the physical well-being of humans, namely, reducing inflammation and pain; supplements, namely, dietary supplements, for medical use and baby food, all the above containing preparations and products resulting from the processing of microorganisms, particularly metabolites obtained from the processing of probiotic bacterial cultures; probiotic and/or nutritional and dietary supplements; antifungal preparations; antifungal creams for medical use; vaginal antifungal preparations; fungal and/or bacterial probiotics, and nutritional supplement for digestive health; nutritional supplement for combating digestive disorders such as Crohn's Disease, ulcerative colitis and irritable bowel syndrome; diagnostic test kit comprised of medical diagnostic reagents and assays for the detection of bacteria, fungus, microorganisms, probiotics, cancer and/or pathogens in the gastrointestinal tract; diagnostic test kit comprised of medical diagnostic reagents and assays for the detection of bacteria, fungus, microorganisms, probiotics, cancer and/or pathogens in the large intestine; diagnostic colon test kit comprised of medical diagnostic reagents and assays for the detection of cancer, polyps, ulcers, inflammation, infection, bacteria and microorganisms; diagnostic colon cancer test kit comprised of medical diagnostic reagents and assays; colorectal cancer screening test kit comprised of medical diagnostic reagents and assaysACTIVE—
041Educational services, namely, providing online instruction and distribution of educational materials in connection therewith featuring information regarding the gastrointestinal tract and the existence and reason for bacteria, fungus, microorganisms, probiotics, cancer and/or pathogens in the gastrointestinal tract; educational services, namely, providing online instruction and distribution of educational materials in connection therewith featuring information regarding the gastrointestinal tract and the existence and reason for bacteria, fungus, microorganisms, probiotics, cancer and/or pathogens in the large intestine; educational services, namely, providing online instruction and distribution of educational materials in connection therewith featuring information regarding the gastrointestinal tract and how to have and maintain and/or monitor a heathy gastrointestinal tract; educational services, namely, providing online instruction and distribution of educational materials in connection therewith featuring information regarding the gastrointestinal tract and how to have and maintain and/or monitor a heathy large intestineACTIVE—
044Medical diagnostic testing services to detect bacteria, fungus, microorganisms, probiotics, cancer and/or pathogens in the gastrointestinal tract; medical diagnostic testing services to detect bacteria, fungus, microorganisms, probiotics, cancer and/or pathogens in the large intestine; medical diagnostic testing services to apprise individuals and/or animals of the status of the gastrointestinal tract; medical diagnostic testing services to apprise individuals and/or animals of the status of the large intestine; providing medical information comprised of a personalized report comparing detected levels of bacteria, fungus, microorganisms, probiotics, cancer and/or pathogen in the gastrointestinal tract; providing medical information comprised of a personalized report comparing detected levels of bacteria, fungus, microorganisms, probiotics, cancer and/or pathogen in the large intestineACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Dec 9, 2019MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Dec 9, 2019ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
May 10, 2019EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
May 8, 2019EX2GSOU EXTENSION 2 GRANTED—
May 8, 2019EXT2SOU EXTENSION 2 FILED—
May 8, 2019EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jan 30, 2019ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Oct 30, 2018EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 26, 2018EX1GSOU EXTENSION 1 GRANTED—
Oct 26, 2018EXT1SOU EXTENSION 1 FILED—
Oct 26, 2018EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
May 8, 2018NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Mar 13, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Mar 13, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 21, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Feb 1, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Feb 1, 2018XAECEXAMINER'S AMENDMENT ENTERED—
Feb 1, 2018GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Feb 1, 2018GNEAEXAMINERS AMENDMENT E-MAILED—
Feb 1, 2018CNEAEXAMINERS AMENDMENT -WRITTEN—
Feb 1, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jan 31, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 31, 2018TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 2, 2017GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 2, 2017GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 2, 2017CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 31, 2017DOCKASSIGNED TO EXAMINER—
Jul 1, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—

Frequently asked questions

Related guidance